Source: Eur Respir J 2011; 38: 1361-1367
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Kavuru M.S., Malur A., Marshall I., Barna B.P., Meziane M., Huizar I., Dalrymple H., Karnekar R., Thomassen M.J.. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J 2011; 38: 1361-1367

Member's Comments

No comment yet.

Related content which might interest you: Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis Source: Eur Respir J 2004; 23: 526-531 Year: 2004 Pulmonary alveolar proteinosis Source: Respipedia Article Year: 2017 Whole lung lavage (WLL) for patients with pulmonary alveolar proteinosis Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004 The benefits of whole lung lavage in pulmonary alveolar proteinosis Source: Eur Respir J 2004; 23: 503-505 Year: 2004 KL-6 in whole lung lavage fluid of patients with pulmonary alveolar proteinosis Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease Year: 2009 Call for an international survey on therapeutic lavage for pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 1049 Year: 2012 Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Idiopathic pulmonary alveolar proteinosis: GM CSF therapy and whole lung lavage a case report Source: Eur Respir J 2003; 22: Suppl. 45, 44s Year: 2003 Pulmonary alveolar proteinosis: failure of treatment by bronchoscopic lobar lavages and GM-CSF treatment in a child Source: Eur Respir J 2003; 22: Suppl. 45, 309s Year: 2003 Determinants of protein concentration in whole lung lavage of patients with pulmonary alveolar proteinosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009 Efficacy of total lung lavage in pulmonary alveolar proteinosis: A multicenter international study of GELF Source: International Congress 2016 – Advancements in bronchoscopy Year: 2016 Therapeutic whole-lung lavage in alveolar proteinosis Source: Annual Congress 2008 - Trends in interventional pulmonology Year: 2008 Whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP): long-term lung function follow-up Source: Eur Respir J 2001; 18: Suppl. 33, 220s Year: 2001 Pulmonary alveolar proteinosis (PAP) - clinical features and response to treatment by bronchofiberoscopic lobar lavage Source: Eur Respir J 2005; 26: Suppl. 49, 541s Year: 2005 Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Lung function and symptom improvement in patients with pulmonary alveolar proteinosis after whole lung lavage or N-acetylcysteine treatment Source: Eur Respir J 2005; 26: Suppl. 49, 83s Year: 2005 Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF Source: Eur Respir J 2002; 20: Suppl. 38, 447s Year: 2002 Pulmonary alveolar proteinosis and long-term outcome after bronchopulmonary lavage Source: International Congress 2017 – Paediatric bronchology Year: 2017 Long term follow up of the whole lung lavage programme in patients with pulmonary alveolar proteinosis: an update Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006 Rituximab therapy in autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1503-1506 Year: 2009